FDA Approves First Drug for Rare Form of Rickets

FRIDAY, April 20, 2018 -- Ultragenyx Pharmaceutical Inc. ' s Crysvita (burosumab-twza) has been approved by the U.S. Food and Drug Administration to treat adults and children ages 1 year and older with x-linked hypophosphatemia (XLH). A clinical trial...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news